
Azenta (AZTA) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
143.4M
Gross Profit
65.9M
45.94%
Operating Income
-12.6M
-8.77%
Net Income
-40.5M
-28.21%
EPS (Diluted)
$-0.88
Balance Sheet Metrics
Total Assets
2.0B
Total Liabilities
340.4M
Shareholders Equity
1.7B
Debt to Equity
0.20
Cash Flow Metrics
Operating Cash Flow
-12.3M
Free Cash Flow
7.0M
Revenue & Profitability Trend
Azenta Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 656.3M | 665.1M | 555.5M | 513.7M | 388.5M |
Cost of Goods Sold | 393.0M | 401.9M | 299.9M | 269.9M | 216.4M |
Gross Profit | 263.4M | 263.1M | 255.6M | 243.8M | 172.1M |
Gross Margin % | 40.1% | 39.6% | 46.0% | 47.5% | 44.3% |
Operating Expenses | |||||
Research & Development | 33.5M | 34.0M | 27.5M | 22.4M | 17.8M |
Selling, General & Administrative | 302.7M | 316.3M | 251.5M | 252.1M | 190.3M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 336.3M | 350.2M | 279.0M | 274.5M | 208.1M |
Operating Income | -72.9M | -87.1M | -23.4M | -30.7M | -35.9M |
Operating Margin % | -11.1% | -13.1% | -4.2% | -6.0% | -9.2% |
Non-Operating Items | |||||
Interest Income | 33.2M | 43.7M | 15.7M | 632.0K | 849.0K |
Interest Expense | - | 0 | 4.6M | 2.0M | 2.9M |
Other Non-Operating Income | -127.6M | 12.9M | -2.2M | -16.9M | -2.3M |
Pre-tax Income | -167.3M | -30.4M | -9.9M | -49.0M | -40.3M |
Income Tax | -3.2M | -17.6M | 1.4M | -20.1M | -13.9M |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -164.2M | -14.3M | 2.1B | 110.7M | 64.9M |
Net Margin % | -25.0% | -2.1% | 384.0% | 21.6% | 16.7% |
Key Metrics | |||||
EBITDA | 145.6M | -15.5M | 31.6M | 18.8M | 28.8M |
EPS (Basic) | $-3.09 | $-0.22 | $28.48 | $1.49 | $0.88 |
EPS (Diluted) | $-3.09 | $-0.22 | $28.48 | $1.49 | $0.88 |
Basic Shares Outstanding | 53175000 | 66253000 | 74897000 | 74229000 | 73557000 |
Diluted Shares Outstanding | 53175000 | 66253000 | 74897000 | 74229000 | 73557000 |
Income Statement Trend
Azenta Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 310.9M | 678.9M | 658.3M | 227.4M | 250.6M |
Short-term Investments | 151.2M | 338.9M | 911.8M | 81.0K | 51.0K |
Accounts Receivable | 172.7M | 156.5M | 163.8M | 119.9M | 94.8M |
Inventory | 115.3M | 128.2M | 85.5M | 60.4M | 37.1M |
Other Current Assets | 80.7M | 98.8M | 132.6M | 51.1M | 44.0M |
Total Current Assets | 832.8M | 1.4B | 2.5B | 777.4M | 649.5M |
Non-Current Assets | |||||
Property, Plant & Equipment | 69.5M | 71.3M | 2.5M | 2.3M | 2.5M |
Goodwill | 1.6B | 1.9B | 1.2B | 1.1B | 1.1B |
Intangible Assets | 248.0M | 294.3M | 178.4M | 186.5M | 212.3M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 11.7M | 4.5M | 58.3M | 251.9M | 152.5M |
Total Non-Current Assets | 1.3B | 1.5B | 1.3B | 1.0B | 909.8M |
Total Assets | 2.1B | 2.9B | 3.7B | 1.8B | 1.6B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 44.4M | 35.8M | 38.7M | 42.4M | 25.7M |
Short-term Debt | - | - | - | - | 827.0K |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | 128.9M | 82.8M |
Total Current Liabilities | 204.8M | 210.9M | 230.5M | 345.1M | 211.1M |
Non-Current Liabilities | |||||
Long-term Debt | 58.8M | 60.4M | 49.2M | 94.8M | 68.5M |
Deferred Tax Liabilities | 54.6M | 67.7M | 66.2M | 15.0M | 36.3M |
Other Non-Current Liabilities | 12.9M | 12.2M | 6.7M | 6.2M | 1.3M |
Total Non-Current Liabilities | 126.2M | 140.3M | 122.2M | 149.1M | 134.5M |
Total Liabilities | 331.1M | 351.2M | 352.7M | 494.2M | 345.7M |
Equity | |||||
Common Stock | 590.0K | 713.0K | 885.0K | 878.0K | 873.0K |
Retained Earnings | 1.5B | 1.6B | 1.7B | -470.1M | -551.1M |
Treasury Stock | 201.0M | 201.0M | 201.0M | 201.0M | 201.0M |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 1.8B | 2.5B | 3.4B | 1.3B | 1.2B |
Key Metrics | |||||
Total Debt | 58.8M | 60.4M | 49.2M | 94.8M | 69.3M |
Working Capital | 628.0M | 1.2B | 2.2B | 432.3M | 438.3M |
Balance Sheet Composition
Azenta Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -164.2M | -14.3M | 2.1B | 110.7M | 64.9M |
Depreciation & Amortization | 90.7M | 85.6M | 53.7M | 65.3M | 65.5M |
Stock-Based Compensation | 14.5M | 9.4M | 10.7M | 27.5M | 16.3M |
Working Capital Changes | 7.9M | -13.7M | -84.4M | -58.6M | -24.5M |
Operating Cash Flow | -62.8M | 29.5M | 2.1B | 127.7M | 116.7M |
Investing Activities | |||||
Capital Expenditures | -37.4M | -39.4M | -73.4M | -52.8M | -39.9M |
Acquisitions | 0 | -386.5M | 2.8B | -95.5M | -15.7M |
Investment Purchases | -405.6M | -236.2M | -2.0B | -151.0K | -10.9M |
Investment Sales | 667.7M | 1.1B | 705.4M | 121.0K | 44.8M |
Investing Cash Flow | 224.7M | 431.4M | 1.5B | -146.3M | -22.7M |
Financing Activities | |||||
Share Repurchases | -661.7M | -838.5M | 0 | 0 | - |
Dividends Paid | 0 | 0 | -7.5M | -29.7M | -29.5M |
Debt Issuance | - | - | - | 0 | 0 |
Debt Repayment | -783.0K | -578.0K | -50.1M | -2.0M | -2.1M |
Financing Cash Flow | -659.2M | -840.5M | -62.8M | -25.9M | -27.0M |
Free Cash Flow | 12.9M | -32.3M | -543.5M | 97.1M | -2.1M |
Net Change in Cash | -497.3M | -379.6M | 3.5B | -44.5M | 67.0M |
Cash Flow Trend
Azenta Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-10.24
Forward P/E
71.05
Price to Book
0.82
Price to Sales
2.05
PEG Ratio
-0.01
Profitability Ratios
Profit Margin
-16.68%
Operating Margin
0.03%
Return on Equity
-9.15%
Return on Assets
-1.60%
Financial Health
Current Ratio
2.76
Debt to Equity
3.15
Beta
1.59
Per Share Data
EPS (TTM)
$-3.25
Book Value per Share
$36.55
Revenue per Share
$14.45
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
azta | 1.4B | -10.24 | 0.82 | -9.15% | -16.68% | 3.15 |
Intuitive Surgical | 168.4B | 65.35 | 9.44 | 16.04% | 28.51% | 0.00 |
Becton, Dickinson | 56.4B | 35.95 | 2.21 | 6.18% | 7.41% | 75.93 |
AtriCure | 1.8B | -39.39 | 3.82 | -7.85% | -7.27% | 16.63 |
Staar Surgical | 1.4B | 49.73 | 4.07 | -25.55% | -42.45% | 12.04 |
Biolife Solutions | 1.2B | -58.89 | 3.48 | -5.66% | -5.92% | 6.86 |
Financial data is updated regularly. All figures are in the company's reporting currency.